Lloyd Damon

MD

Hematologist
Advocate for personalized medicine

About me

Dr. Lloyd Damon is a hematologist and researcher who specializes in blood cancers such as lymphomas and leukemias.

Damon studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was an early investigator of rituximab, the first monoclonal antibody approved to treat human cancer, specifically lymphoma. (Monoclonal antibodies are cancer-fighting molecules produced in the lab and then infused to work with the patient's immune system against cancer.) In 1998, Damon developed a high-dose regimen for mantle cell lymphoma involving autologous stem cell transplants – which use the patient's own stem cells. When studying cytarabine, an important leukemia drug, he discovered the risk factors for an uncommon toxic effect it can have on the brain and then developed a method for modifying the dose that reduces this side effect significantly.

Damon earned his medical degree at the University of Michigan. He completed an internal medicine residency and a fellowship in hematology and oncology at UCSF, where he joined the faculty in 1988. He is deputy chief of the Divisions of Hematology and Medical Oncology.

  • Education

    University of Michigan, 1982

  • Residencies

    UCSF, Internal Medicine, 1985

  • Fellowships

    UCSF, Hematology/Oncology, 1988

  • Board Certifications

    Hematology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

All blood diseases – malignant or benign – are significant, and I take a personalized approach to every patient.

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

My reviews

4.9

Overall Experience
150 Reviews
Dr Damon was extremely thorough diligent patient and clear in explaining to me and my wife and daughter the parameters of my medical condition including prospective treatments and their likely time lines: what might be needed and when what likely wouldnt be needed before there were a change in my condition. I am extremely appreciative of the care and attention I received from Dr Damon.
Explained things in a way that was easy to understand
150 Reviews
Did the doctor pay attention to your concerns
150 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
143 Reviews
Knew the important information about your medical history
148 Reviews
The provider showed respect for what you had to say
148 Reviews
The provider spent enough time with me
147 Reviews

Selected research

Decorative Caduceus

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Mainten...

Relapse-free survival (RFS) will be measured from time of randomization to either leukemia relapse or death, whichever comes first. Leukemia relapse will be defined as bone marrow (BM) blasts 5% or higher (not attributable to rege...

Recruiting

Decorative Caduceus

Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic L...

Recruiting

Decorative Caduceus

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

MTD is defined as the cohort of participants one cohort below the cohort that develop dose-limiting toxicity (DLT) in at least 2 participants.

Recruiting

Decorative Caduceus

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an ...

Recruiting

Share